Merck KGaA plans to construct a new plant in China to manufacture diabetes drugs and address critical healthcare needs of the Chinese population.
The new plant is planned to be built in Shaghai, China covering an area of 40,000 square meters. The plant will have a room for a 20,000-square-meter expansion.
The US$107.67 million (€80 million) plant will manufacture diabetes drugs namely Glucophage, Concor, Euthyrox and also drugs for heart and thyroid conditions.
The construction work is scheduled to start in September 2014 and expected to be completed in 2016. Merck plans to start commercial production in 2017.